Quince Therapeutics Q2 net loss widens on acquisition charges - QNCX News | Rallies
Quince Therapeutics Q2 net loss widens on acquisition charges Q QNCX • 2026-08-14 Outlook
Quince expects Phase 2 data for LAM-001 in BOS in Q1 2027
Phase 2b data for LAM-001 in PH-ILD anticipated in Q1 2028
Company expects cash position to fund operations through end of 2028
Overview
US biopharmaceutical developer completed Orphai acquisition, adding LAM-001 to late-stage pulmonary pipeline
Company closed $115 mln private placement financing, boosting cash to $116 mln as of June 30, 2026
Q2 net loss widened due to acquisition-related charges and increased G&A expenses
Result Drivers
Acquisition-related charges - Net loss increased due to one-time charges from the Orphai acquisition and assumption of historical optionsPipeline expansion - Acquisition of Orphai added LAM-001, advancing late-stage pulmonary disease programsR&D spending shift - Overall R&D expense fell as eDSP program wound down, while LAM-001 costs increased due to study start-up Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Quince Therapeutics, Inc. is $81.00, about 149.9% above its August 13 closing price of $32.41 RAKR
•
2026-09-12
QNCX•
